Wall Street brokerages predict that Quest Diagnostics Inc (NYSE:DGX) will post $1.39 earnings per share for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for Quest Diagnostics’ earnings, with the lowest EPS estimate coming in at $1.34 and the highest estimate coming in at $1.55. Quest Diagnostics posted earnings of $1.31 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 6.1%. The business is scheduled to issue its next earnings report on Thursday, January 25th.

According to Zacks, analysts expect that Quest Diagnostics will report full-year earnings of $5.65 per share for the current financial year, with EPS estimates ranging from $5.62 to $5.67. For the next year, analysts forecast that the firm will post earnings of $5.74 per share, with EPS estimates ranging from $5.53 to $5.88. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that follow Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, October 19th. The medical research company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The business had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.92 billion. During the same period in the previous year, the firm earned $1.37 EPS. The business’s revenue for the quarter was up 2.4% on a year-over-year basis.

DGX has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Canaccord Genuity restated a “buy” rating and set a $118.00 price target on shares of Quest Diagnostics in a report on Wednesday, September 13th. Raymond James Financial restated a “market perform” rating on shares of Quest Diagnostics in a report on Monday, September 25th. Credit Suisse Group cut their price target on shares of Quest Diagnostics from $110.00 to $99.00 and set a “neutral” rating on the stock in a report on Thursday, September 28th. Finally, Zacks Investment Research lowered shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and seven have given a buy rating to the company’s stock. Quest Diagnostics has a consensus rating of “Hold” and an average target price of $106.28.

Shares of Quest Diagnostics (NYSE:DGX) opened at $98.99 on Friday. Quest Diagnostics has a 1-year low of $90.10 and a 1-year high of $112.96. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78. The stock has a market cap of $13,240.12, a P/E ratio of 17.41, a PEG ratio of 2.02 and a beta of 0.60.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 9th will be given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date is Monday, January 8th. Quest Diagnostics’s payout ratio is presently 37.74%.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. grew its position in Quest Diagnostics by 4.7% during the third quarter. Robeco Institutional Asset Management B.V. now owns 1,092,810 shares of the medical research company’s stock valued at $102,331,000 after purchasing an additional 48,921 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in Quest Diagnostics by 4.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 487,316 shares of the medical research company’s stock valued at $54,171,000 after purchasing an additional 18,968 shares in the last quarter. Commonwealth Bank of Australia grew its position in Quest Diagnostics by 6.6% during the second quarter. Commonwealth Bank of Australia now owns 22,604 shares of the medical research company’s stock valued at $2,511,000 after purchasing an additional 1,398 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Quest Diagnostics by 12.7% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 33,104 shares of the medical research company’s stock worth $3,680,000 after acquiring an additional 3,719 shares in the last quarter. Finally, Brighton Jones LLC bought a new stake in Quest Diagnostics in the second quarter worth approximately $224,000. 89.20% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Brokerages Expect Quest Diagnostics Inc (DGX) Will Announce Earnings of $1.39 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/16/brokerages-expect-quest-diagnostics-inc-dgx-will-announce-earnings-of-1-39-per-share.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.